Oncobiologics Stock Price, News & Analysis (NASDAQ:ONS)

$1.42 0.05 (3.65 %)
(As of 11/21/2017 05:05 AM ET)
Previous Close$1.37
Today's Range$1.36 - $1.48
52-Week Range$0.78 - $3.95
Volume459,100 shs
Average Volume106,735 shs
Market Capitalization$33.81 million
P/E RatioN/A
Dividend YieldN/A
Beta-0.43

About Oncobiologics (NASDAQ:ONS)

Oncobiologics logoOncobiologics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on identifying, developing, manufacturing and commercializing biosimilar therapeutics. It is focused on monoclonal antibodies (mAbs) in the disease areas of immunology and oncology. The Company offers BioSymphony Platform. The Company has identified approximately eight biosimilar product candidates, of which two product candidates are ONS-3010 and ONS-1045. ONS-3010 is an adalimumab (Humira) biosimilar. The Company has initiated Phase III preparatory activities for ONS-3010. Its second product candidate, ONS-1045, is a bevacizumab (Avastin) biosimilar. The Company's other preclinical product candidate, ONS-1050, a trastuzumab (Herceptin) biosimilar, interferes with the human epidermal growth factor receptor 2 (HER2). ONS-4010 is a biosimilar to denosumab (Prolia/Xgeva), which is a human mAb. Its other biosimilar product, ONS-1055, is a biosimilar to cetuximab (Erbitux).


Industry, Sector and Symbol:
  • Industry: Biotechnology & Medical Research
  • Sub-Industry: N/A
  • Sector: Medical
  • Symbol: NASDAQ:ONS
  • Previous Symbol: NYSE:ONS
  • CUSIP: N/A
  • Web: www.oncobiologics.com
Debt:
  • Debt-to-Equity Ratio: -0.01%
  • Current Ratio: 0.03%
  • Quick Ratio: 0.03%
Sales & Book Value:
  • Annual Sales: $2.98 million
  • Price / Sales: 11.76
  • Book Value: ($0.23) per share
  • Price / Book: -6.17
Profitability:
  • Net Income: $-53,320,000.00
  • Net Margins: -3,056.85%
  • Return on Assets: -239.07%
Misc:
  • Employees: 83
  • Outstanding Shares: 24,680,000
 

Frequently Asked Questions for Oncobiologics (NASDAQ:ONS)

What is Oncobiologics' stock symbol?

Oncobiologics trades on the NASDAQ under the ticker symbol "ONS."

Where is Oncobiologics' stock going? Where will Oncobiologics' stock price be in 2017?

2 brokerages have issued twelve-month price objectives for Oncobiologics' stock. Their forecasts range from $3.00 to $15.00. On average, they anticipate Oncobiologics' share price to reach $9.00 in the next year. View Analyst Ratings for Oncobiologics.

Who are some of Oncobiologics' key competitors?

Who are Oncobiologics' key executives?

Oncobiologics' management team includes the folowing people:

  • Pankaj Mohan Ph.D., Chairman of the Board, President, Chief Executive Officer (Age 53)
  • Lawrence A. Kenyon, Chief Financial Officer, Corporate Secretary (Age 52)
  • Scott A. Gangloff, Senior Vice President - Development and Manufacturing (Age 43)
  • Stephen J. McAndrew Ph.D., Senior Vice President - Business Strategy & Development (Age 63)
  • Kogan Bao Ph.D., Vice President - Analytical Sciences (Age 47)
  • Elizabeth A. Yamashita, Vice President - Regulatory Affairs (Age 56)
  • Kenneth M. Bahrt M.D., Chief Medical Officer (Age 64)
  • Claudio Albrecht, Director
  • Yezan Haddadin, Director
  • Scott A. Canute, Independent Director (Age 57)

When did Oncobiologics IPO?

(ONS) raised $35 million in an initial public offering (IPO) on Friday, May 13th 2016. The company issued 5,800,000 shares at a price of $6.00 per share. Jefferies and Barclays served as the underwriters for the IPO and Cantor Fitzgerald & Co. was co-manager.

Who owns Oncobiologics stock?

Oncobiologics' stock is owned by a number of of institutional and retail investors. Top institutional shareholders include GMS TENSHI HOLDINGS PTE. LTD (68.60%). View Institutional Ownership Trends for Oncobiologics.

How do I buy Oncobiologics stock?

Shares of Oncobiologics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Oncobiologics' stock price today?

One share of Oncobiologics stock can currently be purchased for approximately $1.42.

How big of a company is Oncobiologics?

Oncobiologics has a market capitalization of $33.81 million and generates $2.98 million in revenue each year. Oncobiologics employs 83 workers across the globe.

How can I contact Oncobiologics?

Oncobiologics' mailing address is 7 CLARKE DRIVE, CRANBURY NJ, 08512. The company can be reached via phone at 609-619-3990 or via email at [email protected]


MarketBeat Community Rating for Oncobiologics (NASDAQ ONS)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  48 (Vote Outperform)
Underperform Votes:  41 (Vote Underperform)
Total Votes:  89
MarketBeat's community ratings are surveys of what our community members think about Oncobiologics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Analysts' Consensus Rating for Oncobiologics (NASDAQ:ONS)

  (How are Consensus Ratings Calculated?)
Ratings Breakdown: 0 Sell Ratings, 1 Hold Rating, 1 Buy Rating, 0 Strong Buy Ratings
Consensus Rating:Buy (Score: 2.50)
Consensus Price Target: $9.00 (533.80% upside)

Consensus Price Target History for Oncobiologics (NASDAQ:ONS)

Price Target History for Oncobiologics (NASDAQ:ONS)

Analysts' Ratings History for Oncobiologics (NASDAQ:ONS)

Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
4/13/2017Cantor FitzgeraldReiterated RatingBuy$15.00LowView Rating Details
4/12/2017Jefferies Group LLCReiterated RatingHold$3.00HighView Rating Details
6/7/2016Barclays PLCReiterated RatingOverweight$11.00N/AView Rating Details
(Data available from 11/21/2015 forward)

Earnings

Earnings History for Oncobiologics (NASDAQ:ONS)


No earnings announcements for this company have been tracked by MarketBeat.com

Estimates

Earnings Estimates for Oncobiologics (NASDAQ:ONS)

No earnings estimates for this company have been tracked by MarketBeat.com

Dividends

Dividend History for Oncobiologics (NASDAQ:ONS)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Oncobiologics (NASDAQ ONS)

Insider Ownership Percentage: 33.50%
Institutional Ownership Percentage: 23.37%
Insider Trades by Quarter for Oncobiologics (NASDAQ:ONS)
Insider Trades by Quarter for Oncobiologics (NASDAQ:ONS)

Insider Trades by Quarter for Oncobiologics (NASDAQ ONS)

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
11/11/2016Scott A. GangloffSVPSell37,369$3.75$140,133.75View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Oncobiologics (NASDAQ ONS)

Source:

Social Media

Financials

Chart

Oncobiologics (NASDAQ ONS) Chart for Tuesday, November, 21, 2017
Loading chart…

This page was last updated on 11/21/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.